Muse cells, short for multilineage-differentiating stress-enduring cells, are a rare type of stem cell found in adult human tissues. Researchers identify them using markers including SSEA-3 and CD105. A single Muse cell can produce cells with characteristics of all three germ layers in laboratory experiments. This broad potential is why they are often described as pluripotent-like cells; it does not mean they can rebuild any damaged organ in a patient. PMC2889306
Muse-cell treatments remain experimental. A Japanese randomized stroke trial treated 25 people with a Muse-cell-based product and 10 with placebo. It reported an early signal of benefit, alongside a serious adverse reaction, but does not establish a routine treatment or a dependable recovery rate. PMC10925866

Where Do Muse Cells Come From?
Mari Dezawa’s team at Tohoku University first reported Muse cells in 2010. They isolated them from cultured human skin fibroblasts, bone marrow stromal cells, and fresh bone marrow aspirates. No embryos or reprogramming genes were needed to obtain them. PMC2889306
Their name describes two laboratory findings. “Multilineage-differentiating” refers to their ability to generate cells representing the three embryonic germ layers: ectoderm, mesoderm, and endoderm. “Stress-enduring” refers to their survival under stressful conditions used in isolation experiments. In suspension culture, they can form clusters expressing markers such as Nanog, Oct3/4, and Sox2. These are laboratory characteristics, not a clinical test showing that an infusion will repair an organ. PMC2889306
How rare are they? In the original study, SSEA-3/CD105 double-positive cells represented about 0.04% of bone marrow-derived mononuclear cells, roughly four in 10,000. In the cultured cell populations tested, SSEA-3-positive cells made up about 1.1% of bone marrow stromal cells and 1.8% of fibroblasts. These measurements depend on the sample, culture conditions, and assay; they are not specifications for a clinic’s cell product. PMC2889306
How Are Muse Cells Different From Other Stem Cells?
Muse cells are studied within the broader field of regenerative medicine, but they are not interchangeable with a general mesenchymal stem or stromal cell preparation. A mixed MSC product and a Muse-enriched product can differ in composition, manufacturing, and evidence. A minority cell fraction does not, by itself, set a numerical ceiling on treatment benefit.
Unlike Muse cells, induced pluripotent stem cells, or iPS cells, are created by reprogramming other cells. However, reprogramming does not always involve inserting genes into the genome: non-integrating methods include Sendai-virus, episomal, and messenger-RNA approaches. PMC4329913
| Cell type | Source | Differentiation potential | Important distinction |
|---|---|---|---|
| Embryonic stem cells | Early embryo | Broad potential across the three germ layers | Undifferentiated cells can form teratomas; safety depends on the final product |
| Induced pluripotent stem cells | Reprogrammed body cells | Broad potential across the three germ layers | Reprogramming need not integrate genes; manufacturing and residual undifferentiated cells require safety controls |
| Tissue-specific adult stem cells | Adult tissues, such as bone marrow | Usually restricted to particular lineages, such as blood cells | Not equivalent to pluripotent cells or to Muse cells |
| Muse cells | Adult mesenchymal tissues and cell populations | Single-cell differentiation across three germ layers reported experimentally | Human tissue replacement and treatment benefit remain unproven for routine care |
In the original Muse-cell experiments, injected cell preparations did not form teratomas in immunodeficient mouse testes during observation lasting up to six months. A teratoma is a tumor containing several tissue types. This finding is relevant to safety research, but it is not proof that every Muse-cell product is cancer-free or safe in humans. PMC2889306
How Might Muse Cells Repair Tissue?
One proposed mechanism is migration toward injury signals. In a rabbit heart-attack model, researchers found that sphingosine-1-phosphate signaling through the S1PR2 receptor helped intravenously administered Muse cells reach damaged heart tissue. Cells also expressed cardiac and vascular markers after transplantation. These were animal experiments, not evidence that an intravenous infusion rebuilds a human heart. 29475983
The original mouse experiments likewise reported transplanted human cells with tissue-associated markers in injured skin, muscle, and liver. Such findings support further investigation; they do not demonstrate enough functional cell replacement to reverse disease in people. PMC2889306
Some human research has used allogeneic, or donor-derived, cells without immunosuppressive drugs. For example, the stroke trial did not use immunosuppression. That describes the trial protocol; it does not guarantee that donor cells cannot provoke an immune response or that another product can use the same approach safely. PMC10925866
What Has Been Tested in People?
CL2020 is the Muse-cell-based investigational product used in the Japanese studies summarized below. Results apply to the tested product, patient group, dose, and route—not to any infusion advertised as containing Muse cells. The reported doses describe research protocols, not dosing recommendations.
| Condition | Study and participants | Treatment and follow-up | Finding and main limitation |
|---|---|---|---|
| ST-elevation heart attack | First-in-human study; 3 patients; no control group | 15 million CL2020 cells once, intravenously; 12 weeks | No adverse drug reactions reported; pumping measures improved, but benefit cannot be separated from recovery or other care. 32522904 |
| Dystrophic epidermolysis bullosa | Phase 1/2 open-label study; 5 participants aged 17–49; 13 selected ulcers; no control group | 15 million cells once, intravenously; 52 weeks | Mean patient-level ulcer-area reduction was 46.3% at week 4; ulcer sizes returned to baseline overall by week 12. PMC8359848 |
| Subacute ischemic stroke | Phase 2 randomized, double-blind trial; 25 treated and 10 placebo recipients | 15 million cells once, intravenously, 14–28 days after stroke; follow-up to 52 weeks | At week 12, 40% versus 10% reached modified Rankin Scale ≤2; one Grade 4 status epilepticus event was classified as an adverse reaction. Small sample and substantial uncertainty. PMC10925866 |
Heart attack
The three heart-attack patients had left ventricular ejection fractions of 45% or less after successful coronary intervention. Ejection fraction describes how much blood the left ventricle pumps out with each contraction. Although pumping measures improved over 12 weeks, this uncontrolled study cannot show how much, if any, improvement came from CL2020 rather than established treatment or natural recovery. 32522904
Blistering skin disease
The skin study tracked 13 ulcers in five people—not 13 independent patients. Its 46.3% mean reduction at week 4 had a very wide confidence interval, including no improvement. Total selected ulcer area decreased significantly at that visit, but this was a different measure, and the overall effect was not sustained to week 12. Reported adverse events included Grade 3 stomach pain; transient arm tingling in one participant was considered possibly related to CL2020 and resolved within 14 days. PMC8359848
Ischemic stroke
The stroke trial’s primary endpoint was safety at 12 weeks. Its key efficacy endpoint was the proportion reaching a modified Rankin Scale score of 2 or less, meaning no more than slight disability. Ten of 25 treated patients reached that threshold, compared with one of 10 placebo recipients. This is a disability outcome at a specified time, not a cure rate. PMC10925866
The 95% confidence intervals were wide: 21.1–61.3% for the treated group and 0.3–44.5% for placebo. The study also compared the treated response with a prespecified 8.7% threshold derived from historical registry data. Passing that threshold is not the same as establishing a precise treatment effect against placebo. By week 12, adverse events occurred in 96% versus 100%, and adverse reactions in 28% versus 10%. An adverse reaction meant that a relationship to treatment could not be ruled out; it did not necessarily mean causation was proven. One treated patient had Grade 4 status epilepticus, a life-threatening seizure condition. PMC10925866
Other early studies
A single-arm study in 10 people with cervical spinal cord injury used one intravenous dose of 15 million cells and monitored safety for up to 52 weeks. Two severe adverse events were judged unrelated to treatment. Without a control group, reported functional changes cannot establish treatment efficacy. PMC11321021
The SHIELD study enrolled nine newborns with moderate-to-severe hypoxic-ischemic encephalopathy who had received therapeutic cooling. Three received 1.5 million cells and six received 15 million, each as one intravenous injection at 5–14 days of age. The primary endpoint was adverse events within 12 weeks. One mild liver-enzyme elevation was considered potentially related and resolved without treatment. The uncontrolled design cannot establish a developmental benefit. 39401019
A separate open-label phase 2 study enrolled five people with amyotrophic lateral sclerosis, or ALS. They received 15 million cells intravenously each month for six doses, with safety and tolerability assessed over 12 months from the first dose. No serious treatment-related adverse effects were reported; a Grade 3 bone fracture was judged unrelated. The reported change in the rate of functional decline was not statistically significant, so the study did not establish that CL2020 slows ALS. PMC10686030
Are Muse Cell Treatments Safe or Approved?
The small studies above cannot establish long-term safety or reliably detect rare harms. The severe seizure reaction in the stroke trial must be considered alongside the absence of reported drug reactions in the three-person heart study. Different diseases, products, doses, and follow-up periods prevent these findings from being combined into one dependable safety rate.
For Japan, CL2020 does not appear in PMDA’s published list of approved regenerative medical products covering April 2015 through July 2026. That dated list is not a worldwide approval assessment or a substitute for checking the exact product’s current authorization. A published study is not a marketing approval. 000283257.pdf
Japan’s regenerative-medicine registration and review framework includes provision-plan submission and certified-committee review. These requirements must not be confused with product marketing approval or proof of clinical benefit. Trial registration also does not demonstrate that a treatment works. En
The US FDA warns that misleading claims about unapproved regenerative products can put patients at risk. Its consumer alert is US regulatory guidance, not a statement of Japanese law. Consumer alert regenerative medicine products including stem cells and exosomes Discuss the full stem cell treatment risk picture and the tested product’s adverse-event record with a doctor independent of the seller.
What Are Muse Cells Not?
- Not a synonym for MSCs. A general MSC preparation is not automatically equivalent to the Muse-cell-based product studied in a clinical trial.
- Not embryonic or induced pluripotent stem cells. Muse cells are isolated from adult tissues rather than obtained from embryos or created by reprogramming other cells.
- Not exosomes, platelets, or a growth-factor mixture. These are different biological products. Evidence for one cannot be transferred to another.
- Not a guaranteed repair system. Three-germ-layer differentiation in a laboratory does not establish restoration of an injured human brain, heart, or spinal cord.
What Should You Ask a Clinic?
If a clinic offers a “Muse-containing MSC infusion” after a stroke, compare the actual product and treatment protocol with the research—not just the cell name. The published stroke trial tested a specific donor-derived product, a single intravenous dose, and a 14–28-day treatment window. It does not establish that another preparation, repeated dosing, or treatment years after a stroke produces the same outcome. PMC10925866
- Identify the product. Ask for its name, tissue source, donor or autologous status, manufacturing process, measured Muse-cell fraction, dose, route, and sterility and release-testing information.
- Match the evidence. Request the published human study for that product and condition. Check the number of patients, comparison group, endpoint, follow-up, and adverse reactions. Ask whether “improvement” means a validated functional outcome or only a laboratory result.
- Verify authorization and aftercare. Request the exact approval or research/provision-plan identifier and ask what it permits. Confirm whether the study is actually recruiting, what standard care continues, the itemized cost, and who manages complications. Registration papers and payment receipts are not evidence of efficacy.
A useful example is the stroke trial’s “40%” result: it meant 10 of 25 participants reached a disability threshold at week 12. It did not mean 40% were cured, nor that you have a 40% chance of recovery with a clinic’s infusion. Bring that distinction—and the reported severe seizure—to an independent medical consultation. PMC10925866
Muse cells are a scientifically interesting adult stem-cell population with broad experimental differentiation potential. The practical question is whether a specific product improves a meaningful outcome safely for people with a particular condition. The small studies summarized here do not yet establish that for routine care. This article provides general information, not personal medical advice.
Have questions about treatment information or appointments in Japan?




